Mark Donovan - Concepedia

Concepedia

Author

Mark Donovan

Bristol-Myers Squibb (United States)

Also Known As

M DONOVAN, M. Donovan, Mark Donovan, Mark N. Donovan

29

Publications

2.8K

Citations

15

H-Index

30

Concepts

All Affiliations

Bristol-Myers Squibb (United States)Sorbonne Université AstraZeneca (United States)Bristol-Myers Squibb (Sweden)McMaster University

MD

About

Mark Donovan is an author at Bristol-Myers Squibb (United States) specializing in medicine, heart failure, and cardiovascular disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	238
2	Public Health	1	1	15
3	Cell Biology	1	1	63
4	Diabetes	1	1	58
5	Health Policy	1	1	15

Mark Donovan

×

15

Publications

2.8K

Citations

14

H-Index

	Year	Citations
Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction Barry M. Massie, Peter E. Carson, John J.V. McMurray, New England Journal of Medicine	2008	1.9K
A Systematic Assessment of Cardiovascular Outcomes in the Saxagliptin Drug Development Program for Type 2 Diabetes Robert Frederich, John H. Alexander, Fred T. Fiedorek, Postgraduate Medicine	2010	218
Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin Anthony Barnett, B Charbonnel, Mark Donovan, Current Medical Research and Opinion	2012	161
Baseline Plasma NT-proBNP and Clinical Characteristics: Results From the Irbesartan in Heart Failure With Preserved Ejection Fraction Trial Robert S. McKelvie, Michel Komajda, John J.V. McMurray, Journal of Cardiac Failure Heart FailureCardiovascular DiseaseMedicineCardiovascular PharmacologyBaseline Plasma Nt-probnp	2009	64
Abstract CT180: Preliminary phase 1 profile of BMS-986179, an anti-CD73 antibody, in combination with nivolumab in patients with advanced solid tumors Lillian L. Siu, Howard A. Burris, Dung T. Le, Cancer Research Preliminary Phase 1ImmunologyImmunoeditingImmunotherapeuticsAbstract Ct180	2018	63
Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials Nayyar Iqbal, Artist Parker, Robert Frederich, Cardiovascular Diabetology	2014	60
Saxagliptin Add-on Therapy to Insulin With or Without Metformin for Type 2 Diabetes Mellitus: 52-Week Safety and Efficacy Anthony Barnett, B Charbonnel, Jia Li, Clinical Drug Investigation Metabolic SyndromeTranslational MedicineSaxagliptin Add-on TherapyDiabetes ManagementInsulin Management	2013	58
Safety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitus Boaz Hirshberg, Artist Parker, Helen K. Edelberg, Diabetes/Metabolism Research and Reviews	2013	55
Apixaban versus no anticoagulation for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma (PREVAPIX-ALL): a phase 3, open-label, randomised, controlled trial Sarah H. O’Brien, Vilmarie Rodriguez, Glen Lew, The Lancet Haematology Hematological MalignancyThrombosisAcute Lymphoblastic LeukaemiaVenous ThrombosisApixaban Versus	2023	38
Clinical and Immunohistochemical Features Associated with a Response to Bortezomib in Patients with Multiple Myeloma Mark A. Dawson, Stephen Opat, Yamna Taouk, Clinical Cancer Research	2009	33

Page 1